May 10, 2022

Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022

May 9, 2022

Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe

May 6, 2022

Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis

April 29, 2022

Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer

April 26, 2022

Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on May 10, 2022

April 12, 2022

Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis

February 25, 2022

Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX® (relugolix) for the Treatment of Advanced Prostate Cancer

February 7, 2022

Myovant Sciences to Present at Upcoming Investor Conferences

January 26, 2022

Myovant Sciences Announces Financial Results for Third Quarter of Fiscal Year 2021 and Corporate Updates

January 12, 2022

Myovant Sciences to Host Third Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on January 26, 2022